SCHEMBL1764981

SCHEMBL1764981

Cc1ncc(-c2cccc(C(F)(F)F)c2)s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
GAA P10253 1/20 0.48
ATM Q13315 1/20 0.48
SCN2A Q99250 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.47
IDO1 P14902 1/20 0.45
DYRK1A Q13627 4/20 0.45
DYRK2 Q92630 4/20 0.45
HDAC6 Q9UBN7 1/20 0.45
IKBKB O14920 1/20 0.44
BRD4 O60885 1/20 0.44
CCNA2 P20248 3/20 0.44
CDK2 P24941 3/20 0.44
CDK5 Q00535 3/20 0.44
CDK5R1 Q15078 3/20 0.44
DYRK1B Q9Y463 3/20 0.44
DYRK3 O43781 2/20 0.44
CCNT1 O60563 2/20 0.44
CDK9 P50750 2/20 0.44
CSF1R P07333 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4513898 0.85 AOC3 (0.45) ALDH1A1GAADYRK1ADYRK2HDAC6
SCHEMBL13018928 0.81 ALDH1A1 (0.49) ALDH1A1GAAATMSCN2ASMN1; SMN2
SCHEMBL40156 0.81 ADORA2A (0.49) ALDH1A1GAAATMSCN2ASMN1; SMN2
SCHEMBL2403212 0.80 HSD17B1 (0.47) IDO1
SCHEMBL3459364 0.80 HSD17B1 (0.54) ALDH1A1SMN1; SMN2IDO1HDAC6
SCHEMBL146522 0.79 KDR (0.52)
SCHEMBL13140798 0.78 ALDH1A1 (0.50) ALDH1A1SCN2ASMN1; SMN2IDO1HDAC6
SCHEMBL1198760 0.77 LOXL2 (0.48) ALDH1A1GAAATMSCN2AIDO1
SCHEMBL14408027 0.77 KCNH2 (0.52) DYRK1A
SCHEMBL2407377 0.77 NPC1 (0.44) ALDH1A1GAASMN1; SMN2IDO1IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288435-B2 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-16 US disclosed
US-20110124636-A1 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-05-26 US disclosed
US-20100331298-A1 Carboxamide Compounds and Their Use CYTOPATHFINDER, INC. (JP) 2010-12-30 US disclosed
US-20100210633-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE EPIX DELAWARE, INC. (US) 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331298-A1 Carboxamide Compounds and Their Use CCR2, CCR1, CCR5 ALDH1A1 1247/4885GAA 3620/4885ATM 3711/4885
US-20100210633-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE CCR2, CCR1, CCR5 ALDH1A1 1247/4885GAA 3620/4885ATM 3711/4885
US-20110124636-A1 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, CNR1 ALDH1A1 807/4885GAA 3257/4885ATM 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.